428 Interim analysis of Phase 2 results for cemiplimab in patients with metastatic basal cell carcinoma (mBCC) who progressed on or are intolerant to hedgehog inhibitors (HHIs)
Main Authors: | Marcus Butler, Rogerio Neves, Lisa Licitra, Israel Lowy, Zeynep Eroglu, Karl Lewis, Leonel Hernandez-Aya, Axel Hauschild, Emmanuel Okoye, Siyu Li, Jean-Francois Baurain, Oliver Bechter, Ketty Peris, Aleksandar Sekulic, Alexander Stratigos, Lara Dunn, Anne Lynn Chang, Michael Migden, Kosalai Mohan, Ebony Coates, Emily Ruiz, Frank Seebach, David Weinreich, George Yancopoulos, Timothy Bowler, Matthew Fury |
---|---|
Format: | Article |
Language: | English |
Published: |
BMJ Publishing Group
2020-11-01
|
Series: | Journal for ImmunoTherapy of Cancer |
Similar Items
-
Cemiplimab for Cisplatin Resistant Metastatic Penile Cancer
by: Chloé Denis, et al.
Published: (2021-06-01) -
Intravascular squamous cell carcinoma treated with cemiplimab
by: Alexander N. Rose, BS, et al.
Published: (2021-08-01) -
Phase 2 study of cemiplimab in patients with metastatic cutaneous squamous cell carcinoma: primary analysis of fixed-dosing, long-term outcome of weight-based dosing
by: Thomas Eigentler, et al.
Published: (2020-06-01) -
391 A first-in-human study of intratumoral SAR441000, an mRNA mixture encoding IL-12sc, interferon alpha2b, GM-CSF and IL-15sushi as monotherapy and in combination with cemiplimab in advanced solid tumors
by: Evelyna Derhovanessian, et al.
Published: (2020-11-01) -
Metastatic cutaneous squamous cell carcinoma responsive to cemiplimab in a patient with multiple myeloma
by: Nareh Valerie Marukian, MD, et al.
Published: (2020-09-01)